Mason Hawkins's BIO Position Overview
Mason Hawkins (via Southeastern Asset Management Inc/Tn/) currently holds 0 shares of Bio-Rad Laboratories, Inc. (BIO) worth $0, representing 0.00% of the portfolio. First purchased in 2023-Q2, this medium-term investment has been held for 13 quarters.
Based on 13F filings, Mason Hawkins has maintained a strategic position in BIO, demonstrating sustained confidence in this investment. Largest addition occurred in Q4 2023, adding 37,956 shares. Largest reduction occurred in Q2 2026, reducing 162,804 shares.
Analysis based on 13F filings available since 2013 Q2
Mason Hawkins's Bio-Rad Laboratories (BIO) Holding Value Over Time
Track share changes against reported price movement
Quarterly Bio-Rad Laboratories (BIO) Trades by Mason Hawkins
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q2 2026 | -162,804 | Sold Out | 0 | $0.00 |
| Q1 2026 | -64,826 | Reduce 28.48% | 162,804 | $278.75 |
| Q4 2025 | -9,624 | Reduce 4.06% | 227,630 | $302.99 |
| Q3 2025 | -78,031 | Reduce 24.75% | 237,254 | $280.39 |
| Q2 2025 | -8,520 | Reduce 2.63% | 315,285 | $241.32 |
| Q1 2025 | +15,336 | Add 4.97% | 323,805 | $243.56 |
| Q4 2024 | -9,867 | Reduce 3.10% | 308,469 | $328.51 |
| Q3 2024 | -6,677 | Reduce 2.05% | 318,336 | $334.58 |
| Q2 2024 | -18,946 | Reduce 5.51% | 325,013 | $273.11 |
| Q1 2024 | -20,099 | Reduce 5.52% | 343,959 | $345.87 |
| Q4 2023 | +37,956 | Add 11.64% | 364,058 | $322.89 |
| Q3 2023 | +583 | Add 0.18% | 326,102 | $358.45 |
| Q2 2023 | +325,519 | New Buy | 325,519 | $379.12 |
Mason Hawkins's Bio-Rad Laboratories Investment FAQs
Mason Hawkins first purchased Bio-Rad Laboratories, Inc. (BIO) in Q2 2023, acquiring 325,519 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Mason Hawkins has held Bio-Rad Laboratories, Inc. (BIO) for 13 quarters since Q2 2023.
Mason Hawkins's largest addition to Bio-Rad Laboratories, Inc. (BIO) was in Q2 2023, adding 325,519 shares worth $123.41 M.
According to the latest 13F filing for Q2 2026, Mason Hawkins's firm, Southeastern Asset Management Inc/Tn/, owns 0 shares of Bio-Rad Laboratories, Inc. (BIO), valued at approximately $0.
As of the Q2 2026 filing, Bio-Rad Laboratories, Inc. (BIO) represents approximately 0.00% of Mason Hawkins's publicly disclosed stock portfolio, making it one of their key holdings.
Mason Hawkins's peak holding in Bio-Rad Laboratories, Inc. (BIO) was 364,058 shares, as reported at the end of Q4 2023.